Der gastroösophageale Reflux, auch GERD genannt (gastroesophageal reflux disease) ist mit einer Prävalenz von 20–30% der erwachsenen Bevölkerung ein weit verbreitetes Problem. Davon abzugrenzen ist der häufig in der HNO-Praxis anzutref-fende laryngopharyngeale Reflux (LPR), bei dem es sich um eine durch den Magensäurereflux bedingte Entzündung der oberen Atemwege handelt. Die Unterschiede im klinischen Bild charakterisieren die widersprüchliche Beziehung der beiden klinischen Entitäten und erschweren die Diagnosestellung. Darüber hinaus muss ein besonderes Augenmerk auf Beschwerden des Magen- und Darmtrakts gelegt und deren Behandlung nicht vernachlässigt werden. Neben diätetischen Ratschlägen zählen einige pflanzliche Arzneimittel zu den Therapieoptionen. Alginate, die ein Aufstossen verhindern, bewähren sich in der Praxis. Kombinationsarzneimittel aus der europäischen und tibetischen Tradition spielen eine wesentliche Rolle in der Behandlung, nicht nur des LPR sondern auch bei Verdauungsproblemen des oberen und unteren Verdauungstrakts, wie Reizmagen und Reizdarm.

1.
Pearson
JP
,
Parikh
S
,
Orlando
RC
,
Johnston
N
,
Allen
J
,
Tinling
SP
, et al.
Review article: reflux and its consequences—the laryngeal, pulmonary and oesophageal manifestations. Conference held in conjunction with the 9th International Symposium on Human Pepsin (ISHP) Kingston-upon-Hull, UK, 21-23 April 2010
.
Aliment Pharmacol Ther
.
2011
Apr
;
33
Suppl 1
:
1
71
.
[PubMed]
0269-2813
2.
Printza
A
,
Kyrgidis
A
,
Oikonomidou
E
,
Triaridis
S
.
Assessing laryngopharyngeal reflux symptoms with the Reflux Symptom Index: validation and prevalence in the Greek population
.
Otolaryngol Head Neck Surg
.
2011
Dec
;
145
(
6
):
974
80
.
[PubMed]
0194-5998
3.
Koufman
JA
,
Amin
MR
,
Panetti
M
.
Prevalence of reflux in 113 consecutive patients with laryngeal and voice disorders
.
Otolaryngol Head Neck Surg
.
2000
Oct
;
123
(
4
):
385
8
.
[PubMed]
0194-5998
4.
Book
DT
,
Rhee
JS
,
Toohill
RJ
,
Smith
TL
.
Perspectives in laryngopharyngeal reflux: an international survey
.
Laryngoscope
.
2002
Aug
;
112
(
8 Pt 1
):
1399
406
.
[PubMed]
0023-852X
5.
Koufman
JA
.
The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury
.
Laryngoscope
.
1991
Apr
;
101
(
4 Pt 2
Suppl 53
):
1
78
.
[PubMed]
0023-852X
6.
Ossakow
SJ
,
Elta
G
,
Colturi
T
,
Bogdasarian
R
,
Nostrant
TT
.
Esophageal reflux and dysmotility as the basis for persistent cervical symptoms
.
Ann Otol Rhinol Laryngol
.
1987
Jul-Aug
;
96
(
4
):
387
92
.
[PubMed]
0003-4894
7.
Vaezi
MF
.
“Refractory GERD”: acid, nonacid, or not GERD?
Am J Gastroenterol
.
2004
Jun
;
99
(
6
):
989
90
.
[PubMed]
0002-9270
8.
Ylitalo
R
,
Thibeault
SL
.
Relationship between time of exposure of laryngopharyngeal reflux and gene expression in laryngeal fibroblasts
.
Ann Otol Rhinol Laryngol
.
2006
Oct
;
115
(
10
):
775
83
.
[PubMed]
0003-4894
9.
Johnston
N
,
Dettmar
PW
,
Bishwokarma
B
,
Lively
MO
,
Koufman
JA
.
Activity/stability of human pepsin: implications for reflux attributed laryngeal disease
.
Laryngoscope
.
2007
Jun
;
117
(
6
):
1036
9
.
[PubMed]
0023-852X
10.
Kawamura
O
,
Aslam
M
,
Rittmann
T
,
Hofmann
C
,
Shaker
R
.
Physical and pH properties of gastroesophagopharyngeal refluxate: a 24-hour simultaneous ambulatory impedance and pH monitoring study
.
Am J Gastroenterol
.
2004
Jun
;
99
(
6
):
1000
10
.
[PubMed]
0002-9270
11.
Agréus
L
,
Svärdsudd
K
,
Nyrén
O
,
Tibblin
G
.
Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time
.
Gastroenterology
.
1995
Sep
;
109
(
3
):
671
80
.
[PubMed]
0016-5085
12.
Gibson
PR
.
History of the low FODMAP diet
.
J Gastroenterol Hepatol
.
2017
Mar
;
32
Suppl 1
:
5
7
.
[PubMed]
0815-9319
13.
Barrett
JS
.
How to institute the low-FODMAP diet
.
J Gastroenterol Hepatol
.
2017
Mar
;
32
Suppl 1
:
8
10
.
[PubMed]
0815-9319
14.
Frakturgefahr durch Säurehemmer
.
MMW Fortschr Med
.
2007
;
149
(
3
):
3
.1438-3276
15.
FDA
Safety Announcement
. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. 25.
Mai
2010
.
16.
WU HH et al. Association Between Recent Use of Proton Pump Inhibitors and Nontyphoid Salmonellosis: A Nested Case-Control Study. Clin Infect Dis.
2014
Dec
1
; 59(11): 1554–1558.
17.
Tariq
R
,
Singh
S
,
Gupta
A
,
Pardi
DS
,
Khanna
S
.
Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis
.
JAMA Intern Med
.
2017
Jun
;
177
(
6
):
784
91
.
[PubMed]
2168-6106
18.
Kenneth
EL
.
McColl und Derek Gillen: Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy
.
Gastoenterology
.
2009
;
137
:
20
2
.
19.
McGlashan
JA
,
Johnstone
LM
,
Sykes
J
,
Strugala
V
,
Dettmar
PW
.
The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux
.
Eur Arch Otorhinolaryngol
.
2009
Feb
;
266
(
2
):
243
51
.
[PubMed]
0937-4477
20.
Wilkie
MD
,
Fraser
HM
,
Raja
H
.
Gaviscon® Advance alone versus co-prescription of Gaviscon® Advance and proton pump inhibitors in the treatment of laryngopharyngeal reflux
.
Eur Arch Otorhinolaryngol
.
2018
Oct
;
275
(
10
):
2515
21
.
[PubMed]
0937-4477
21.
Reimer
C
,
Lødrup
AB
,
Smith
G
,
Wilkinson
J
,
Bytzer
P
.
Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor
.
Aliment Pharmacol Ther
.
2016
Apr
;
43
(
8
):
899
909
.
[PubMed]
0269-2813
22.
Pilichiewicz
AN
. Effects of Iberogast® on Proximal Gastric Volume, Antropyloroduodenal Motility and Gastric Emptying in Healthy Men. The American Journal of Gastroenterology. 2007.102;6:1276-1283.
23.
Liu
CY
,
Müller
MH
,
Glatzle
J
,
Weiser
D
,
Kelber
O
,
Enck
P
, et al.
The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine
.
Neurogastroenterol Motil
.
2004
Dec
;
16
(
6
):
759
64
.
[PubMed]
1350-1925
24.
Melzer
J
,
Rösch
W
,
Reichling
J
,
Brignoli
R
,
Saller
R
.
Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast)
.
Aliment Pharmacol Ther
.
2004
Dec
;
20
(
11-12
):
1279
87
.
[PubMed]
0269-2813
25.
Balsiger
BM
,
Krayer
M
,
Rickenbacher
A
,
Flogerzi
B
,
Vennos
C
,
Gschossmann
JM
.
Tibetan herbal formula Padma Digestin modulates gastrointestinal motility in vitro
.
World J Gastrointest Pharmacol Ther
.
2013
Feb
;
4
(
1
):
9
15
.
[PubMed]
2150-5349
26.
Meier
R
,
Hengstler
P
,
Weber
F
,
Maurer
H
,
Bommeli
C
,
Brignoli
R
.
The Tibetan herbal formula Padma Digestin in functional dyspepsia: an open-label study
.
Forsch Komplement Med
.
2013
;
20
(
s2
Suppl 2
):
2
7
.
[PubMed]
1661-4119
27.
Monographie BGA/BfArM (Kommission E)
: „Helenii radix (Alantwurzel)“. Bundesanzeiger.
1988
Mai
5
;85
28.
Cardamom seed (Cardamomi fructus) Published
November
30
,
1985
;
29.
Kim
I
,
Bae
J
,
Kim
BJ
.
Carthami flos regulates gastrointestinal motility functions
.
Integr Med Res
.
2017
Dec
;
6
(
4
):
404
8
.
[PubMed]
2213-4220
30.
Jurenka
JS
.
Therapeutic applications of pomegranate (Punica granatum L.): a review
.
Altern Med Rev
.
2008
Jun
;
13
(
2
):
128
44
.
[PubMed]
1089-5159
31.
Chinese Pharmacopoeia Commission, Institute of Medicinal Plant Development, Chinese Acadamy of Sciences
.
II
.
A Colored Identification Atlas of Chinese Materia Medica and Plants as specified in the Pharmacopoeia of the People’s Republic of China
.
Volume I
.
Peking, China
:
People's Medical Publishing House
;
2010
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.